News

PharmaGap Inc. announces collaboration with Queen's University at Kingston, Ontario to investigate the potential for development of PharmaGap's lead cancer drug GAP-107B8 in bladder cancer.

Study Designed to Position AMR101 as First-in-Class Drug for Treating High Triglyceride Levels in Statin-Treated Patients with Mixed Dyslipidemia.

With a grant of $475,000, the Michael J. Fox Foundation is funding preclinical development of a vaccine against Parkinson's disease by AFFiRiS AG. The vaccine, known as PD01, targets the protein alpha-synuclein and might offer for the first time a possibility for a treatment that can slow or stop the progression of Parkinson's disease.

LMTX, poised to enter phase III, in development as a potential neurodegeneration disease modifying agent with a patent life extending to 2027.

Novasep Process and Danisco announces the scale-up of an innovative process for the production of natural betaine. The plant will be the first to exploit a new extraction process using vinasse, a byproduct of sugar-beet-derived bioethanol.

Imperial Innovations Group plc, a leading technology commercialisation and investment group, announces the merger of its portfolio company Myotec Therapeutics Ltd. (Myotec) with Hybrid Biosystems Ltd. (Hybrid) to form PsiOxus Therapeutics.

SymBio Pharmaceuticals Limited announces the launch of TREAKISYM® (SyB L-0501, bendamustine hydrochloride) in Japan for the treatment of refractory/relapsed low-grade B-cell non-Hodgkin’s lymphoma and mantle cell lymphoma.

Zealand Pharma announces the receipt of a EUR 500,000 milestone payment as part of its license agreement with Helsinn Healthcare for the development of ZP1846 for the treatment of chemotherapy-induced diarrhoea.

This strategic agreement will help accelerate development of Rhenovia’s unique technology and enable AFM to explore new avenues for the treatment of neurological diseases.

With the strong growth in biologics, large molecules, and biopharmaceutical therapeutics in recent years, the pharmaceutical and biotech industries are increasingly turning towards peptides and proteins in the search for drug discovery targets.